Abstract
Drug-induced urine discoloration, although usually benign, can still raise concern in healthcare facilities. This case report presents the second case of purple urine discoloration associated with cefiderocol in a 64-year-old male admitted to the intensive care unit for ventilator-associated pneumonia. The patient required broad-spectrum antibiotic treatment with vancomycin, cefiderocol, amikacin, and micafungin. On the fourth day after initiating antibiotics, the presence of purplish urine in the foley bag was noted. Urinalysis showed 11-25 red blood cells/hpf, but cultures ruled out urinary tract infection. Further laboratory workup did not reveal any evidence of hemolysis or rhabdomyolysis. Cultures from the endotracheal aspirate grew multidrug-resistant Pseudomonas. Cefiderocol and amikacin were continued to complete a seven-day course. Two days after completion of the cefiderocol course, the urine discoloration cleared up, providing strong evidence that cefiderocol was the cause of the discoloration.
Recommended Citation
Shaik, Mohammed Rifat; Shaik, Nishat Anjum; Hossain, Sarah; Yunasan, Elvina; Khachatryan, Aleksan; and Chow, Robert
(2023)
"Purplish Discoloration of Urine in a Patient Receiving Cefiderocol: A Rare Adverse Effect,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 13:
Iss.
6, Article 10.
DOI: 10.55729/2000-9666.1256
Available at:
https://scholarlycommons.gbmc.org/jchimp/vol13/iss6/10